KYORIN Pharmaceutical Co., Ltd.

4569.T
Drug Manufacturers - Specialty & Generic
2026/03/03 Updated
Market Cap: $620.1M (¥97.5B)
Stock Price: $10.79 (¥1,697)
Exchange Rate: 1 USD = ¥157.23

Stock Price Chart

2026/03/03 Updated
10.45
PER (Price Earnings Ratio)
vs Industry Avg: +0.9
0.70
PBR (Price to Book Ratio)
vs Industry Avg: -0.6
3.36%
Dividend Yield
vs Industry Avg: +0.41%

Price Trend

2026/03/03 Updated
Short-term
5-Day MA
-0.64%
Near-term
25-Day MA
+2.08%
Mid-term
75-Day MA
+8.68%
Long-term
200-Day MA
+12.35%

Price & Trading Details

2026/03/03 Updated

PRICE

Previous Close ¥1,725
Open ¥1,723
High ¥1,723
Low ¥1,685
Close ¥1,697

TRADING

Volume 149,300
Average Volume 120,756
Turnover ¥3億
Min. Purchase ¥169,700

Analyst Recommendations 1 analysts

Updated 2026/03/01
Strong Buy
0
Buy
0
Hold
0
Sell
0
Strong Sell
0
Target Price (Mean)
¥1,300
None
¥1,300
High
¥1,300
Median
¥1,300
Low
-19% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Earnings Calendar

Updated 2026/03/01
MAY
12
2026
Next Earnings Release
Q2 FY2026
69days

Recent Earnings

Date EPS Est. EPS Actual Surprise
2015/05/12 ¥28.10 ¥33.53 +19.3%
2015/02/01 ¥79.00 ¥81.32 +2.9%
2014/05/08 ¥37.50 ¥36.84 -1.8%
2014/02/03 ¥65.60 ¥65.26 -0.5%

Shareholder Composition

Updated 2026/03/01
33.0%
Insider Holdings
22.1%
Institutional
44.9%
Public Float
66
Institutional Holders
Insider Holdings 33.0%
Institutional 22.1%
Public Float 44.9%

Major Holders

Updated 2026/03/01
Institution Ownership Shares Change
ADVISORS' INNER CIRCLE FUND II-KOPERNIK GLOBAL ALL-CAP FUND
3.11%
1.9M -10.49%
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
0.95%
569.8K 0.00%
iShares Trust-iShares Core MSCI EAFE ETF
0.90%
541.9K 0.00%
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
0.55%
331.6K 0.00%
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
0.32%
190.1K +4.16%
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
0.31%
185.9K +10.85%

Dividend History 1Years Growth

Updated 2026/03/01
-%
Dividend Yield
¥57
Annual Dividend
+9.6%
YoY Growth
36.0%
Payout Ratio
Year Dividend Change
2025 ¥57 +9.6%
2024 ¥52 0.0%
2023 ¥52 0.0%
2022 ¥52 -20.0%
2021 ¥65 -

Financial Performance

2026/03/01 Updated

No financial data available

Latest IR Information

Latest News (5 items)

Company Information

English Name KYORIN Pharmaceutical Co., Ltd.
Japanese Name 杏林製薬(株)
Stock Code 4569.T (JPX)
Sector / Industry Healthcare / Drug Manufacturers - Specialty & Generic
Website https://www.kyorin-pharm.co.jp
Employees 1,998

About

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance